Cancer vaccine

A cancer vaccine is a vaccine that treats existing cancer or prevents the development...

A cancer vaccine is a vaccine that treats existing cancer or prevents the development of cancer in certain high-risk individuals.Vaccines that treat existing cancer are known as therapeutic cancer vaccines.

There are currently no vaccines able to prevent cancer in general.

Some types of cancer, such as cervical cancer and some liver cancers, are caused by viruses (known as oncoviruses), and traditional vaccines against those viruses, such as HPV vaccine and hepatitis B vaccine, will prevent those types of cancer. These anti-viral vaccines are not further discussed in the rest of this article.

Report: Cancer Vaccine Partnering Terms and Agreements

A cancer vaccine is a vaccine that treats existing cancer or prevents the development of cancer in certain high-risk individuals.

Vaccines that treat existing cancer are known as therapeutic cancer vaccines.

There are currently no vaccines able to prevent cancer in general.

Some types of cancer, such as cervical cancer and some liver cancers, are caused by viruses (known as oncoviruses), and traditional vaccines against those viruses, such as HPV vaccine and hepatitis B vaccine, will prevent those types of cancer. These anti-viral vaccines are not further discussed in the rest of this article.

Cancer vaccine partnering

Cancer vaccine partnering is on the increase according to a recent partnering analysis.

New approaches to cancer vaccines are proving successful in early studies.

This shows promise in the cancer vaccine market according to industry analysis.

Our database Current Agreements reveals the trends in cancer vaccine partnering which has increased significantly since 2007 with a peak in 2010.

There has been a decline in partnering activity since then but market forecasts suggest a gradual pick up in the upward trend.

Surprisingly, bigpharma companies are not the most actively involved in cancer vaccine dealmaking whereas the following companies have shown promise in active dealmaking in this sector:

  • ImmunoCellular Therapeutics
  • Advaxis
  • Scancell
  • Immunovaccine

The majority of the cancer vaccine deals are in the discovery and development stage whereby the licensee obtains a right or an option to license the licensors cancer vaccine technology.

For further details see our article: Industry analysis: Cancer vaccine partnering on the rise

Report: Cancer Vaccine Partnering Terms and Agreements

An example of a deal term entered by Novartis and Transgene for $974 million is as follows:

Novartis, Transgene: Licensing, option, manufacturing, supply and co-promotion agreement for TG4010 (MVA-MUC1-IL2)

Exclusive option agreement with Novartis for the development and commercialisation of Transgene’s targeted immunotherapy product, TG4010 (MVA-MUC1-IL2), for the first-line treatment of non-small cell lung cancer (NSCLC) and other potential cancer indications.

Pursuant to the agreement, Transgene has granted Novartis an option to acquire an exclusive worldwide license for TG4010 and Novartis will pay Transgene a $10 million non-refundable option fee.

Contingent upon the exercise of the option by Novartis and the achievement of successful development, regulatory and commercial milestones in various indications, Transgene is eligible to receive up to a total of approximately €700 million.

According to the agreement, Transgene will initially fund and retain control over the next clinical development phase of TG4010, which is a pivotal, global phase IIb/III clinical trial that Transgene currently anticipates starting by the end of 2010.

In accordance with the option agreement, Novartis will have up to 90 days after receiving results from Transgene for this phase IIb portion to exercise its option.

If the option is exercised:

  • Novartis will assume all development, regulatory and commercialisation costs related to TG4010 across all indications.
  • Transgene will receive a non-refundable licence issuance fee and further milestones contingent upon successful development for various indications and the achievement of longer-term commercialisation targets.
  • Transgene will receive royalties on global sales.
  • Transgene will retain co-promotion rights in certain countries including France and China.
  • Transgene will retain primary manufacturing rights for TG4010 to supply Novartis’ clinical and commercial requirements.

Transgene and Novartis will now form a joint working group to oversee the implementation of the TG4010 global development program.

Read: more on cancer vaccine deals in pharma, biotech, life science partnering deal news, insights and glossary

Report: Cancer Vaccine Partnering Terms and Agreements

Report: Vaccine Partnering Terms and Agreements

Report: Oncology Partnering Terms and Agreements

Print Friendly, PDF & Email